Even when we further potentiated the NK-cell anti-MM response via antibody-dependent cell-mediated cytotoxicity (ADCC), by combining NK-cells and daratumumab (anti-CD38), KIR ligand mismatched NK cells degranulated more robustly than their matched counterparts (63). Here, CD38 is linked to Miyoshi myopathy.